Vitamin B-12 Therapy — CPB 0536 | AETNA Coverage Update

TL;DR: Aetna modified CPB 0536 governing Vitamin B-12 therapy coverage, effective September 26, 2025. Here's what billing teams need to know before claims go out the door.

This update to the Aetna Vitamin B-12 therapy coverage policy touches HCPCS codes J3420 and J3425 for injectable B-12 — cyanocobalamin and hydroxocobalamin — plus CPT 83090 for homocysteine testing. If your practice bills B-12 injections for any Aetna members, or if you support oncology teams where pemetrexed (Alimta) is on the table, this policy sits squarely in your billing queue. The code list runs deep — 473 ICD-10 diagnosis codes — and the medical necessity criteria are specific. Get this wrong, and you're looking at a claim denial on a high-volume service.

---

Quick-Reference: CPB 0536 Aetna Vitamin B-12 Therapy Policy Update 2025

Field	Detail
Payer	Aetna
Policy	Vitamin B-12 Therapy — CPB 0536
Policy Code	CPB 0536
Change Type	Modified
Effective Date	September 26, 2025
Impact Level	High
Specialties Affected	Primary care, internal medicine, hematology, oncology, gastroenterology, neurology
Key Action	Audit all active Aetna B-12 injection claims against the updated ICD-10 diagnosis list and medical necessity criteria before September 26, 2025

---

Aetna Vitamin B-12 Therapy Coverage Criteria and Medical Necessity Requirements 2025

The CPB 0536 policy covers B-12 injections as medically necessary under specific conditions. The two covered injectable formulations are J3420 (cyanocobalamin, up to 1,000 mcg) and J3425 (hydroxocobalamin, 10 mcg). Coverage applies to intramuscular or subcutaneous administration. That route distinction matters — bill the wrong route and you'll trigger a denial.

Aetna defines specific medical necessity criteria for B-12 injection coverage under CPB 0536. Billing teams should review the full policy text for the complete criteria list. Services outside the covered indications are not covered under this policy.

CPT 83090 (homocysteine) is covered when selection criteria are met. If you're billing 83090 without meeting those criteria, expect scrutiny.

The policy also addresses B-12 supplementation in patients receiving pemetrexed (Alimta) — a chemotherapy agent used across multiple cancer types. Aetna covers this combination, but the diagnosis code has to match the cancer type and the clinical context of pemetrexed administration. The ICD-10 list for this indication is extensive.

Prior authorization requirements for B-12 therapy under this policy are not explicitly called out in the CPB 0536 data. Many Aetna commercial plans layer prior authorization requirements on top of CPB coverage criteria. Check the member's plan documents or contact Aetna provider services directly before submitting. If you're not sure, loop in your billing consultant before the September 26 effective date.

---

Aetna Vitamin B-12 Therapy Exclusions and Non-Covered Indications

CPT 64450 — injection of anesthetic agent and/or steroid to other peripheral nerve or branch — is listed in the policy as related to the CPB but is not covered for B-12 therapy purposes. If your team has ever billed 64450 in conjunction with a B-12 diagnosis, flag that claim pattern now.

The policy specifies covered indications for injectable B-12. Services that fall outside those indications are not covered. Review the full CPB 0536 policy text to confirm which clinical scenarios qualify.

CPT 96372 (therapeutic, prophylactic, or diagnostic injection — subcutaneous or intramuscular) is listed as a related code in CPB 0536. It's the administration code you'd pair with J3420 or J3425. Billing 96372 without the corresponding drug code — or pairing it with the wrong diagnosis — is a common pattern that generates denials. Confirm your charge capture links these codes correctly.

---

Coverage Indications at a Glance

---

Aetna Vitamin B-12 Therapy Billing Guidelines and Action Items 2025

These are the steps your billing team should complete before September 26, 2025.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Vitamin B-12 Therapy Under CPB 0536

Covered HCPCS Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
J3420	HCPCS	Injection, vitamin B-12 cyanocobalamin, up to 1,000 mcg — covered for intramuscular or subcutaneous use
J3425	HCPCS	Injection, hydroxocobalamin, 10 mcg

Covered CPT Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
83090	CPT	Homocysteine

Other CPT and HCPCS Codes Related to CPB 0536

These codes appear in the policy but are not primary B-12 therapy codes. Coverage depends on clinical context.

Key ICD-10-CM Diagnosis Codes Covered Under CPB 0536

This is a partial list of the 473 ICD-10-CM codes in the policy. These represent the major diagnostic categories. The full list is available in the CPB 0536 policy document.

The remaining 393 ICD-10 codes in CPB 0536 cover additional oncologic diagnoses, deficiency states, malabsorption conditions, and neurological indications. If your practice treats any of these cancer types with pemetrexed — or manages B-12 deficiency across any specialty — review the full policy at app.payerpolicy.org/p/aetna/0536.

---

The Real Issue with This Policy

The pemetrexed connection is where billing teams get caught flat-footed. Oncology practices often split drug administration and supportive care across separate claims or billing entities. When B-12 supplementation is bundled into a pemetrexed regimen, the claim for J3420 or J3425 needs to clearly tie to the cancer diagnosis — not a generic "nutritional deficiency" code.

If you're billing J3420 with a generic deficiency ICD-10 code and the patient is actually in a pemetrexed protocol, you're underdocumenting. That's money left exposed. Fix the diagnosis mapping at the order level — not after the claim drops.

Vitamin B-12 billing also has a history of fraud scrutiny. Aetna knows this. Any unusual billing pattern — high volume or missing medical necessity documentation — will draw attention. Your reimbursement depends on clean documentation, not just clean codes.

---